J Biol Chem, Vol. 274, Issue 42, 30182-30189, October 15, 1999
Characterization of Osf1, an Osteoblast-specific Transcription
Factor Binding to a Critical cis-acting Element in the Mouse
Osteocalcin Promoters*
Thorsten
Schinke
and
Gerard
Karsenty§
From the Department of Molecular and Human Genetics, Baylor College
of Medicine, Houston, Texas 77030
 |
ABSTRACT |
To elucidate the mechanisms of
osteoblast-specific gene expression we are studying the regulation of
osteocalcin, the most osteoblast-specific gene. Previous
studies of OG2, one of the two mouse osteocalcin genes,
identified two osteoblast-specific cis-acting elements, OSE1 and OSE2,
the latter being the binding site of Cbfa1, the only
osteoblast-specific transcription factor known to date. Here we show
that OSE1 is a cis-acting element as important as OSE2 for the
osteoblast-specific expression of OG2 in cell culture and
transgenic mice. We also show that OSE1 is present in the promoter of
several osteoblast-specific genes including Cbfa1 itself.
These biological features demonstrate the importance of OSE1 and led us
to further characterize this site and the factor binding to it,
provisionally termed Osf1. We first defined the core OSE1 sequence,
5'-TTACATCA-3', which is necessary and sufficient for Osf1 binding to
DNA. This sequence has no strong homology to any known transcription
factor-binding sites. As a first step in identifying Osf1, we performed
an analytical purification of this protein using nuclear extracts from
two different osteoblastic cell lines. We purified Osf1 to homogeneity
through a five-step procedure including a renaturation experiment and found that its apparent molecular mass is 40 kDa. In conclusion, this
study indicates the existence of multiple osteoblast-specific cis-acting elements of equal importance in controlling OG2
promoter activity and provides the first biochemical characterization
of Osf1, a novel osteoblast-specific transcription factor.
 |
INTRODUCTION |
The osteoblast, a cell type of mesenchymal origin, is the only
cell responsible for bone matrix deposition, also called bone formation
(1). Bone formation is a physiological process of critical importance
as it is involved in skeletal growth, bone remodeling, and fracture
repair (2). Diseases affecting bone formation, whether they are
genetically inherited like osteogenesis imperfecta, or acquired like
osteoporosis, are common and very often debilitating (3-7). This
underscores the biomedical importance of elucidating the genetic basis
of osteoblast-specific gene expression and osteoblast differentiation.
It is likely, as it is the case in many cell lineages (8-11), that
these two processes are related and that cell differentiation along the
osteoblastic lineage is controlled, at least in part, by
cell-specific transcription factors which need to be identified. In an
effort to identify these factors we have embarked on a long-term study
of the regulation of OG2, one of the two mouse osteocalcin
genes, whose expression is strictly osteoblast-specific.
Previously, the analysis of the OG2 promoter defined a
147-bp1 fragment that confers
osteoblast-specific expression to a reporter gene in vitro
(12). Within this short OG2 promoter fragment we defined two
osteoblast-specific cis-acting elements, termed OSE1 and OSE2
(originally designated as regions A and C, respectively), that are
characterized by two important features. First, multimers of each of
these elements confer osteoblast specific activity to a heterologous
promoter. Second, OSE1 and OSE2 serve as binding sites for distinct
factors that are only detected in nuclear extracts of osteoblasts but
of no other cell types or tissues tested (12). These osteoblast
specific binding activities were named Osf1 and Osf2,
respectively. Further analysis of Osf2 revealed that it is the
product of the Cbfa1 gene (13). We, and others have
subsequently demonstrated that Cbfa1 acts as a
transcriptional activator of osteoblast differentiation in mouse and
human (13-17).
To date Cbfa1 remains the only osteoblast-specific
transcription factor identified (18). However, several lines of
evidence suggest that other cell-specific transcription factors are
involved in the control of gene expression in osteoblasts. For
instance, multiple investigators have identified osteoblast-specific
cis-acting elements in the promoter elements of the genes encoding
1(I) collagen, bone sialoprotein, insulin-like growth factor 1, and osteocalcin (19-25). Likewise, as mentioned above, we have shown that
OSE1 binds an osteoblast-specific factor that is not Cbfa1 (12).
Although OSE1 has been poorly characterized so far, Osf1, the factor
binding to it, has one important property. Osf1 is present in nuclear
extracts of primary osteoblasts at the earliest stage of cellular
differentiation, but is absent in nuclear extracts of differentiated
osteoblasts that are surrounded by a mineralized matrix (12). Thus,
Osf1 is not only an osteoblast-specific but also a stage-specific
transcription factor that could conceivably act upstream of
Cbfa1, provided that OSE1 has a biologic function.
The present study was aimed at defining the functional importance of
OSE1 and characterizing Osf1. We first demonstrate that OSE1 is as
important as OSE2 for OG2 expression in cell culture and
transgenic mice. We identified an 8-bp core OSE1 sequence that is also
present in the promoter of other osteocalcin genes and of the mouse
Cbfa1 gene. The absence of overt homologies between OSE1 and
other binding sites of known transcription factors suggests that Osf1
may be a novel factor and led us to perform an analytical purification.
This purification showed that Osf1 is a single polypeptide with an
apparent molecular mass of 40 kDa. This is the first step toward
identifying and eventually cloning a cDNA encoding Osf1, a second
osteoblast-specific transcription factor.
 |
EXPERIMENTAL PROCEDURES |
DNA Constructions--
The oligonucleotides used in this study
are presented in Table I. Construction of the p1316-luc and
p147-luc plasmids has been described previously (12).
p147-mOSE2-luc was generated by inserting the
PvuII-SalI fragment of p647-mOSE2a-luc
(26) into p4luc, a promoterless luciferase expression
vector. A 2-bp mutation in OSE1 within p1316-luc was
generated by a two-step polymerase chain reaction method (27). The
primers used for this mutagenesis were 5'-CTTATAGAACCCAAGACCATGGC-3'
(
674/
652), 5'-CTCCTCCTGCAAACATCAGAGAGC-3' (
68/
45),
5'-GCTCTCTGATGTTTGCAGGAGGAG-3' (
45/
68), and 5'-TGGTCGACTTGTCTGT-3'
(+13/+3). p147-mOSE1-luc was generated by inserting the
PvuII-SalI fragment of p1316-mOSE1-luc into p4luc. Six copies of the wild-type or mutated
OSE1Cbfa1 oligonucleotide were cloned into the SmaI
site of the p34-luc construct that has been described
previously (12). Sequences of the generated plasmids were verified by
automatic DNA sequencing.
Cell Culture and DNA Transfections--
Cell culture media and
supplements were purchased from Life Technologies, Inc. ROS17/2.8
osteoblasts were cultured in Dulbecco's modified Eagle's medium/F-12,
F9 teratocarcinoma cells in Eagle's minimal essential medium, C1
mesenchymal cells, and C2 myoblasts in Dulbecco's modified Eagle's
medium. All media were supplemented with 10% fetal bovine serum.
Primary cultures of newborn mouse osteoblasts were prepared and
maintained as described previously (12). DNA transfection experiments
were carried out using the calcium phosphate coprecipitation method as
described (12) with 10 µg of reporter plasmid constructs and 2 µg
of pSV-
Gal to quantitate the transfection efficiency. All
transfections were repeated at least four times in triplicate with
different DNA preparations.
Generation and Analysis of Transgenic Mice--
The constructs
p1314-luc and p1314-mOSE1-luc were digested by
BamHI. Inserts were purified by two rounds of agarose gel
electrophoresis and injected into the pronuclei of fertilized B6D2F1
mouse oocytes (Charles River Laboratories). The injected oocytes were
implanted in the oviducts of pseudopregnant CD1 foster mothers (Jackson ImmunoResearch Laboratories, Inc.) for development to term. Animals expressing the transgenes were identified by screening for luciferase activity in tails. Three founder animals carrying the wild-type construct and two founder animals carrying the mutant construct were
obtained. The copy number of integrated DNA sequence was determined in
F1 generation animals as described previously (26). Luciferase
activities in tissues was assessed in F1 generation animals at 10 days
of age. Organs were dissected and homogenized in buffer containing 100 mM Tris (pH 7.8) and 1 mM dithiothreitol. Protein homogenates were centrifuged, and supernatants were assayed for
luciferase activity as described (26).
Nuclear Extracts and DNA Binding Assays--
Nuclear extracts
from cultured cells were prepared by the method of Dignam et
al. (28). All buffers contained 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 10 µg/ml
leupeptin and pepstatin. Nuclear extracts from isolated tissues of
newborn mice were prepared according to the method of Deryckere and
Gannon (29). For electrophoretic mobility shift assays (EMSA)
double-stranded oligonucleotides were labeled with
[
-32P]ATP and T4 polynucleotide kinase, filled in with
the Klenow fragment of DNA polymerase I, and purified on a
polyacrylamide gel. Approximately 5 fmol of the probe was incubated
with 1-5 µg of nuclear extracts or 1 µl of purified Osf1 in 10 µl of buffer A (50 mM Tris, pH 7.5, 20% glycerol, 100 mM NaCl, 2 mM EDTA, 0.1% Nonidet P-40, 1 mM dithiothreitol) for 10 min at room temperature. 2 µg
of poly(dI-dC) and 250 fmol of single-stranded oligonucleotides were
included as nonspecific competitors. Samples were separated by
electrophoresis on a 5% polyacrylamide gel in 0.25 × TBE at 160 V for 90 min. The gels were dried and autoradiographed.
Purification of Osf1--
The analytical purification of Osf1
was performed from 30 ml of nuclear extract of ROS17/2.8 or C1 cells.
The purification was monitored at every stage by EMSA using the
OSE1
oligonucleotide as a probe. One Osf1 binding unit was defined as the
amount of protein required to retard 0.25 fmol of the probe. Total
protein concentrations were measured by the Bio-Rad protein assay. The nuclear extract was brought to 25% ammonium sulfate saturation at
4 °C over a 30-min period. Precipitated proteins were spun down at
15,000 × g for 15 min, dissolved in 5 ml of buffer A, and dialyzed against the same buffer for 3 h with two buffer
changes. Dialyzed proteins were applied onto a 5-ml phosphocellulose
column (Whatman P11). After washing the column with 5 volumes of buffer A containing 0.2 M NaCl, bound proteins were eluted in 1-ml
fractions with 0.5 M NaCl in buffer A. Fractions containing
Osf1 binding activity were pooled, dialyzed as described above, and
applied onto a MonoQ column that was run using a fast pressure liquid chromatography system (Amersham Pharmacia Biotech). After a washing step with 0.2 M NaCl the proteins were eluted by a 0.2-1
M NaCl gradient in buffer A over 10 min. Osf1 binding
activity was eluted at a NaCl concentration between 0.35 and 0.4 M. The corresponding fractions were pooled, dialyzed
against buffer A, and incubated for 10 min with 14 µg/ml poly(dI-dC),
200 fmol/µl single-stranded OSE1 oligonucleotide, and 100 fmol/µl
double-stranded mutant
OSE1 oligonucleotide (
OSE1-mut4). This
mixture was applied to a 1-ml DNA affinity column containing
multimerized
OSE1 oligonucleotide that was prepared as described by
Kadonaga and Tjian (30). After a washing step at 0.2 M
NaCl, the Osf1 activity was eluted with buffer A containing 0.5 M NaCl. To verify the purity of the eluted Osf1 the final
EMSA was performed with both wild-type and mutant
OSE1
oligonucleotide in the absence of nonspecific competitor DNA.
SDS-PAGE and Renaturation--
SDS-polyacrylamide gel
electrophoresis was carried out as described by Laemmli (31). Proteins
were visualized by silver staining according the method of Heukeshoven
and Dernick (32). 5-mm gel slices were cut out from an adjacent lane
that was run on the same gel, but not stained. These gel slices were
crushed with a pestle and soaked in 500 µl of elution buffer (50 mM Tris, pH 7.5, 0.1 mM EDTA, 0.1% SDS, 5 mM dithiothreitol, 150 mM NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 100 µg/ml bovine serum
albumin) for 3 h at room temperature. Eluted proteins were
precipitated with 80% acetone, dissolved in 50 µl of buffer A
containing 6 M guanidine-HCl, and denatured for 30 min.
After removal of the guanidine by a 10-desalting gel spin column
(Bio-Rad) the proteins were allowed to renature for 2 h at room
temperature. 3 µl of renaturated proteins were assayed for Osf1
binding activity by EMSA using the wild-type and mutant
OSE1
oligonucleotides as probes.
 |
RESULTS |
OSE1 and OSE2 Are Equally Important for OG2 Promoter Activity in
Cell Culture--
To determine the relative importance of OSE1
compared with OSE2 for OG2 expression we introduced small
substitution mutations into either one of these two elements in the
context of a p147-luc reporter gene construct that contains
the first 147 bp of the mouse OG2 promoter fused to the
luciferase gene (luc) (12). These mutations abolish the DNA
binding activity of Osf1 and Cbfa1 to their respective
binding sites (Fig. 8B and Ref. 12). Using the wild-type and
mutated p147-luc constructs we performed DNA transfection
experiments in ROS17/2.8 osteoblasts (Fig.
1A). We chose ROS17/2.8 cells
to perform these experiments because these cells were used in the
initial characterization of OSE1 and OSE2 (12).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
OSE1 is required for OG2 promoter activity in vitro. DNA
transfection experiments in ROS17/2.8 osteoblasts were performed with
wild-type and mutated p147-luc (A) and
p1316-luc (B) reporter gene constructs. Mutated
elements are indicated in gray. Transfection efficiencies
were normalized by co-transfection of a pSV-LacZ construct and
determination of -galactosidase activities in the cell extracts
(12). Values represent the percentage of activity compared with the
wild-type constructs and are the average of five independent
experiments. C, core sequences of the wild-type and mutant
osteoblast-specific elements OSE1 and OSE2. Mutated nucleotides are
indicated in boldface.
|
|
A 2-bp mutation introduced into OSE2 decreased the activity of
p147-luc 85% confirming the critical role of OSE2 for
OG2 expression (Fig. 1A). Likewise, a 2-bp
mutation in OSE1 led to a 76% decrease of p147-luc activity
(Fig. 1A). These results indicate that OSE1 is virtually as
important as OSE2 for OG2 expression. We also introduced the
same 2-bp mutation into OSE1 in the context of a longer 1316-bp
OG2 promoter fragment and performed DNA transfection experiments in ROS17/2.8 cells with the wild-type and mutated p1316-luc constructs (Fig. 1B). The OSE1 mutation
led to a 51% decrease of p1316-luc activity indicating that
even in this larger OG2 promoter fragment the presence of
OSE1 is required for maximal activity in cell culture.
OSE1 Is Critical for OG2 Promoter Activity in Vivo--
As a
further demonstration of the functional importance of OSE1 for
osteocalcin expression, we generated transgenic mice
carrying either the wild-type p1316-luc or the mutated
p1316-luc chimeric genes. Three founder animals carrying the
wild-type and two founder animals carrying the mutant chimeric gene
were obtained. Transgenic mice of the F1 generation from these founder
animals were analyzed for luciferase expression in various
organs at 10 days of age (Fig. 2). In all
mice containing the wild-type p1316-luc transgene the
relative luciferase activities in bone were between 3000 and 5000 per
100 µg of total protein (Fig. 2A). In these mice
luciferase activities in other tissues were less than 1% compared with
the values we measured in bone (2-30/100 µg of protein). This
bone-specific luciferase expression was also observed in all
mice carrying the mutated p1316-luc transgene (Fig.
2B). However, the luciferase activities in long bones of
these latter mice were in average 75% decreased (700-1300/100 µg of
protein) compared with what was observed in long bones obtained from
mice carrying the wild-type transgene (Fig. 2B). Taken
together, these data demonstrate that OSE1 is functionally as important
as OSE2 for OG2 expression, both in cell culture and
in vivo. The functional importance of OSE1 was an incentive
to better characterize this element and the factor binding to it,
thereafter termed Osf1.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
OSE1 is required for OG2 promoter activity in vivo. Transgenic mice
were generated carrying the wild-type (A) or mutated
(B) 1316-bp OG2 promoter fused to the luciferase
reporter gene. Luciferase activities were measured in tissues of
10-day-old F1 animals derived from different founders for each
genotype. Luciferase activities are expressed as light units/100 µg
of protein. Values are the mean of four to six transgenic mice per
founder animal. Error bars represent the standard
deviation.
|
|
Osf1 Binds to an 8-bp Core OSE1 Sequence--
The OSE1
oligonucleotide that was used for EMSA in our previous study covered a
relatively large region of the OG2 promoter consisting of 35 bp (12). Originally, we did not find any motifs within this region
sharing similarities to binding sites of known transcription factors.
To abolish Osf1 binding to DNA we originally used a large mutation
affecting 6 bp (Table I). By definition
this mutation of a large number of base pairs did not allow us to
determine precisely the nucleotides critical for protein binding. We
reasoned that by defining a shorter Osf1-binding site we may be in a
better position to identify key nucleotides within OSE1 and to
recognize binding sites of known transcription factors.
View this table:
[in this window]
[in a new window]
|
Table I
Oligonucleotides used in this study
The core OSE1 sequence is underlined. Mutations are indicated in
boldface. Oligonucleotides harboring single bp mutations are presented
in Fig. 4A.
|
|
To achieve this goal we first assayed shorter OSE1 oligonucleotides for
Osf1 binding activity by EMSA (data not shown). This led us to the
definition of a shorter oligonucleotide spanning only 22 bp of the
OG2 promoter that we termed
OSE1 (Table I). To
demonstrate that the same nuclear activity is binding to the OSE1 and
the
OSE1 oligonucleotide, direct binding and DNA competition experiments were performed by EMSA using nuclear extracts of ROS17/2.8 osteoblasts as a source of protein (Fig.
3). We previously described the presence
of three protein-DNA complexes formed upon incubation of ROS17/2.8
nuclear extracts with the OSE1 oligonucleotide in EMSA (12). Osf1,
defined by its osteoblast-specific presence and its heat lability, is
part of the complex of intermediate mobility. Using the
OSE1
oligonucleotide as a probe in EMSA the same three complexes were
detected (Fig. 3A, lane 1). The complex of intermediate
mobility was specifically competed by the wild-type, but not by the
mutant
OSE1 and OSE1 oligonucleotides (Fig. 3A, lanes
2-5). Likewise, when using the OSE1 oligonucleotide as a probe in
EMSA the Osf1-DNA complex was specifically competed by the wild-type,
but not by the mutant
OSE1 and OSE1 oligonucleotides (Fig. 3B,
lanes 2-5). These results suggest that the same nuclear protein
binds to both the OSE1 and
OSE1 oligonucleotide. This was further
demonstrated by the osteoblast-specific nature of the factor binding to
OSE1 (Fig. 5A). Thus, we used the
OSE1 oligonucleotide
as a probe for the DNA binding experiments described below.

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 3.
OSE1 and OSE1
oligonucleotides bind the same nuclear activity. EMSA was
performed with ROS17/2.8 nuclear extracts using the OSE1
(A) or the OSE1 oligonucleotide (B) as a probe.
Competition experiments were carried out with a 100-fold molar excess
of unlabeled wild-type OSE1 oligonucleotide (lane 2),
mutant OSE1 oligonucleotide (lane 3), wild-type OSE1
oligonucleotide (lanes 4), or mutant OSE1 oligonucleotide
(lane 5). The Osf1-DNA complex is indicated by an
arrow.
|
|
To identify the critical base pairs within the OSE1 sequence that are
required for Osf1 binding to DNA we mutagenized individually 8 bp
within the
OSE1 oligonucleotide (Fig.
4A). The use of these various
OSE1 oligonucleotides in EMSA allowed us to define an 8-bp core OSE1
sequence: 5'-TTACATCA-3' (Fig. 4B).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 4.
Definition of the core OSE1 sequence.
A, summary of the mutational analysis of OSE1. The core OSE1
sequence is shown in boldface. The presence (+) or absence ( ) of Osf1
binding activity is indicated. B, DNA binding to
wild-type (lane 1) or mutant (lanes 2-9) OSE1
oligonucleotides was analyzed by EMSA using nuclear extracts of
ROS17/2.8 cells as a source of protein. The Osf1-DNA complex is
indicated by a closed arrowhead. The open
arrowhead marks a complex of slower mobility that binds to the
OSE1-mut5 oligonucleotide.
|
|
OSE1 Appears to be a Unique Sequence--
Analysis of the core
OSE1 sequence failed to show a strong homology to any known
transcription factor-binding sites. However, a closer inspection of
this 8-bp sequence showed a weak similarity with the cAMP-responsive
element (CRE) whose sequence is 5'-TGACGTCA-3' (33). This led us to
explore the possibility that Osf1 could be a member of the CREB
(CRE-binding proteins) family of transcription factors.
The guanosine present in position 5 of the CRE is known to be critical
for the binding of CREB proteins to DNA (34). Importantly, when we used
a mutant
OSE1 oligonucleotide carrying an A to G mutation in
position 5 of the core OSE1 sequence (
OSE1-mut5) as a probe in EMSA
with ROS17/2.8 nuclear extracts, the Osf1-DNA complex was absent and
replaced by a complex of slower mobility (Fig. 4, lane 6).
To determine wether the factor binding to the
OSE1-mut5
oligonucleotide was osteoblast-specific, EMSA with nuclear extracts of
various tissues and of primary osteoblasts was performed (Fig.
5). While Osf1, the factor binding to the
OSE1 oligonucleotide, was present only in nuclear extracts of non-mineralized primary osteoblasts (Fig. 5A, lane 8), the
factor binding to the
OSE1-mut5 oligonucleotide was present in
nuclear extracts of every tissue tested (Fig. 5B). Moreover,
this latter factor was heat-stable (Fig. 5B, lanes
9-13) as described for CREB proteins (35), unlike Osf1, whose
binding to DNA is abolished upon heating (Fig. 7 and Ref. 12). In
summary, the ubiquitous nature and the heat stability of the factor
binding to the
OSE1-mut5 oligonucleotide clearly distinguishes it
from Osf1. Thus, Osf1 is most likely not a member of the CREB family of
transcription factors, and the core OSE1 sequence appears to be
unique.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 5.
Osteoblast-specific nature of Osf1. EMSA
was performed with nuclear extracts of various tissues and primary
osteoblasts using the OSE1 (A) or the OSE1-mut5
(B) oligonucleotide as a probe. The binding reactions shown
in lanes 9-13 of panel B were performed with
nuclear extracts that were heated for 5 min at 65 °C. Nuclear
extracts used were from skin (sk), heart (he),
kidney (ki), brain (br), lung (lu),
muscle (mu), liver (li), non-mineralized primary
osteoblasts (nmi ob), and mineralized primary osteoblasts
(mi ob). The Osf1-DNA complex is indicated by a closed
arrowhead. The open arrowhead marks a complex of slower
mobility that binds to the OSE1-mut5 oligonucleotide.
|
|
The Core OSE1 Sequence Is Present in the Mouse Cbfa1
Promoter--
The definition of the core OSE1 sequence allowed us to
search for OSE1 sites in other genes that are expressed in osteoblasts. OSE1 is present at the same location in the promoter of OG1,
the other mouse osteocalcin gene (36). We were not able to
locate additional copies of OSE1 in more distal promoter regions of the mouse osteocalcin genes. When we searched the 5'-region of
the mouse gene encoding the osteoblast-specific transcription factor Cbfa1 (kindly provided to us by Dr. P. Ducy), we found one
OSE1 site located 3700 bp upstream of the transcriptional start site. This site is homologous, but not identical to the OSE1 site present in
the OG2 promoter. In particular the surrounding
sequences are totally different. Nevertheless, given the restricted
expression of Cbfa1, we analyzed whether this sequence,
termed OSE1Cbfa1, could act as an osteoblast-specific
cis-acting element.
Six copies of the wild-type or mutant OSE1Cbfa1 oligonucleotide
were cloned upstream of a minimal OG2 promoter fragment in a
luciferase expression vector (p34-luc). This minimal
promoter fragment lacks OSE1 and OSE2 and has virtually no
transcriptional activity in DNA transfection experiments (12). The
multimerized wild-type OSE1Cbfa1 oligonucleotide conferred
osteoblast-specific activity to this promoter fragment in DNA
transfection experiments as the luciferase expression was at
least 30-fold higher in ROS17/2.8 cells compared with F9
teratocarcinoma cells and C2C12 myoblasts, two cell lines that do not
express Cbfa1 (Fig.
6A). In contrast, multimerized mutant OSE1Cbfa1 oligonucleotide failed to increase the
activity of the minimum OG2 promoter.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 6.
Presence of a functional OSE1 element in the
mouse Cbfa1 promoter. A, DNA
transfection experiments in ROS17/2.8 osteoblasts, F9 teratocarcinoma
cells, and C2C12 myoblasts were performed with reporter gene constructs
containing six copies of either the wild-type or the mutant
OSE1Cbfa1 oligonucleotide cloned upstream of a minimal
OG2 promoter-luciferase chimeric gene
(p34-luc). Data represent the ratios of luciferase to
-galactosidase activities and are the average of five independent
experiments. Error bars represent the standard deviation.
B, EMSA was performed with nuclear extracts of
non-mineralized primary osteoblasts (lanes 1-3) and of
various tissues (lanes 4-9). Competition experiments were
performed using a 50-fold molar excess of either the OSE1Cbfa1
(lane 2) or the OSE1 oligonucleotide (lane 3).
Nuclear extracts used were from non-mineralized primary osteoblasts
(nmi ob), mineralized primary osteoblasts (mi
ob), skin (sk), kidney (ki), brain
(br), muscle (mu), and liver (li). The
Osf1-DNA complex is indicated by the arrow. C,
EMSA was performed with nuclear extracts of non-mineralized primary
osteoblasts using the OSE1 oligonucleotide as a probe. Competition
experiments were performed using a 50-fold molar excess of either the
OSE1Cbfa1 (lane 2) or the OSE1 oligonucleotide
(lane 3). The Osf1-DNA complex is indicated by the
arrow.
|
|
Additionally, DNA binding and competition experiments by EMSA were
performed to determine if OSE1Cbfa1 serves as a binding site
for Osf1. When using nuclear extracts of different tissues and
non-mineralized primary osteoblasts as a source of protein, and the
OSE1Cbfa1 oligonucleotide as a probe, an osteoblast-specific
complex migrating at the same location as the Osf1-
OSE1 complex was
observed (Fig. 6B). This protein-DNA complex was competed by
the wild-type
OSE1 and OSE1Cbfa1 oligonucleotides (Fig.
6B, lanes 2 and 3). When using the
OSE1 oligonucleotide as a probe in EMSA the Osf1-DNA complex was also competed by both the
OSE1 and the OSE1Cbfa1 oligonucleotide
(Fig. 6C, lanes 2 and 3). Taken
together, these functional and biochemical lines of evidence indicate
that the Cbfa1 promoter contains at least one OSE1-like site
whose sequence is partially identical to the one present in the
OG2 promoter and that can act as an osteoblast-specific element.
Osf1 Can Be Purified to Homogeneity--
The lack of overt
homology of the core OSE1 sequence to any known transcription
factor-binding sites excluded a polymerase chain reaction based or
low-stringency hybridization approach to cloning a cDNA encoding
Osf1. Therefore we decided to purify Osf1 from osteoblast nuclear
extracts in order to obtain amino acid sequence information. In a
survey of various osteoblastic and mesenchymal cell lines we found one
mesenchymal, pluripotent cell line, C1 (37), expressing high levels of
Osf1. When performing EMSA with nuclear extracts of C1 cells, we
observed only one complex, unlike what was seen with ROS17/2.8 nuclear
extracts (Fig. 7, lanes 1 and
2). As it was the case for the Osf1 activity present in
ROS17/2.8 nuclear extracts, this complex was heat-sensitive (Fig.
7, lane 3) and was not observed when using as probes any of
the eight
OSE1 oligonucleotides harboring single base pair mutations
that were used to define the core OSE1 sequence (Fig. 7, lanes
4-11) indicating that this protein-DNA complex contains Osf1.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 7.
Osf1 is present in C1 mesenchymal cells.
DNA binding to the wild-type (lanes 1 to 3) or
mutant (lanes 4-11) OSE1 oligonucleotides was analyzed
by EMSA using nuclear extracts of ROS 17/2.8 cells
(lane 1) and C1 mesenchymal cells (lanes
2-11) as a source of protein. The binding reaction
shown in lane 3 was perfomed with nuclear extract that was
heated for 5 min at 42 °C. The Osf1-DNA complex is indicated by a
closed arrowhead. The open arrowhead marks a
complex of slower mobility that binds to the OSE1-mut5
oligonucleotide.
|
|
Given the higher level of Osf1 expression and the existence of a single
protein-DNA complex in EMSA, C1 nuclear extracts were chosen as a
source of protein for our purification approach. However, we also
confirmed the results obtained with C1 cells by purifying Osf1 with the
same strategy from ROS17/2.8 nuclear extracts. Fig. 8A summarizes the strategy
used to purify Osf1 on an analytical scale. The presence and integrity
of Osf1 was monitored at each step by EMSA using the
OSE1
oligonucleotide as a probe. Enrichment of Osf1 in the purified
fractions was estimated by comparing the Osf1 binding activity to the
total amount of protein.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 8.
Osf1 can be purified to homogeneity.
A, summary of the analytical purification using nuclear
extracts of C1 mesenchymal cells as a source of protein. One unit was
defined as the amount of Osf1 required to retard approximately 0.25 fmol of the radiolabeled OSE1 oligonucleotide in EMSA, representing
5% retardation in our assay. Total protein concentrations were
determined using the Bio-Rad Protein Assay. Footnote 1, no
detectable protein concentration using 5 µl of the fraction.
B, EMSA with Osf1 purified from C1 (lanes 1 to
4) or ROS 17/2.8 cells (lanes 5 and
6) using the wild-type (lanes 1 and 5) or mutant
(lanes 2 and 6) OSE1 oligonucleotide and the wild-type
(lane 3) or mutant (lane 4) OSE1Cbfa1
oligonucleotide as probes. Nonspecific competitor DNA, poly(dI-dC), was
excluded in this experiment.
|
|
Nuclear extracts were first subjected to a 25% ammonium sulfate
precipitation. Osf1 activity was only detectable in the precipitated fraction. The precipitate was dissolved in buffer A containing 0.1 M NaCl, dialyzed against the same buffer, and applied to a phosphocellulose cation exchange resin where Osf1 activity was eluted
at 0.5 M NaCl. These two steps led to a 20-fold enrichment of Osf1 binding activity (Fig. 8A). Following dialysis
against buffer A containing 0.1 M NaCl, the Osf1 containing
fractions were applied onto a Mono Q anion exchange column. Osf1 was
eluted from this column at a salt concentration between 0.35 and 0.4 M NaCl. After these three initial purification steps we
estimated that Osf1 was enriched more than 75-fold compared with
nuclear extracts (Fig. 8A). The last step of the
purification scheme was a DNA affinity column using the multimerized
OSE1 oligonucleotide coupled to a Sepharose matrix (30). The
fractions containing Osf1 were dialyzed against buffer A containing 0.1 M NaCl and applied onto the DNA affinity resin. Nonspecific
interactions of other proteins with this resin were significantly
reduced by preincubating the protein sample with poly(dI-dC),
single-stranded OSE1 oligonucleotide, and a double-stranded mutant
oligonucleotide (
OSE1-mut4). Specific Osf1 binding activity was
eluted from this column at a concentration of 0.5 M NaCl.
To demonstrate that the purified protein using this procedure was Osf1
we performed EMSA using the wild-type and mutant
OSE1 and
OSE1Cbfa1 oligonucleotides as probes in the absence of
nonspecific competitor DNA (Fig. 8B). The purified protein
bound specifically to the wild-type
OSE1 and OSE1Cbfa1
oligonucleotides, but not to their mutant counterparts (Fig. 8B). Knowing the amount of radiolabeled oligonucleotide
added to the binding reaction, we estimated the final concentration of
the purified Osf1. The yield of Osf1 starting from 30 ml of nuclear
extract was approximately 150 fmol. Thus, the four-step purification
procedure led at least to a 5000-fold purification of Osf1 (Fig.
8A). Using the same procedure we were also able to purify
the specific Osf1 binding activity from ROS 17/2.8 cells. Osf1 purified
from ROS 17/2.8 nuclear extracts behaves like Osf1 purified from C1
cells in EMSA (Fig. 8B, lanes 5 and 6).
The Apparent Molecular Mass of Osf1 is 40 kDa--
When we
performed an SDS-PAGE and silver staining at this stage of the
purification, we observed that the eluate of the DNA affinity resin
contained two distinct polypeptides migrating at 40 and 45 kDa,
respectively (Fig. 9A). To
determine which of these polypeptides contains the Osf1 binding
activity, a renaturation experiment was performed. Aliquots of the DNA
affinity eluate fraction were subjected to SDS-PAGE, the proteins were
eluted from 5-mm gel slices, precipitated by acetone, and subjected to denaturation with 6 M guanidine. After removal of the
guanidine the proteins were allowed to renature and finally assayed for Osf1 binding activity by EMSA using the wild-type or mutant
OSE1 oligonucleotide as a probe (Fig. 9B). Specific Osf1 binding
activity was recovered from the gel slice containing the polypeptide
migrating at 40 kDa (Fig. 9B, gel slice B). This
binding activity was only observed when using the wild-type
OSE1
oligonucleotide as a probe, but was absent when using the mutant
OSE1 oligonucleotide as a probe (Fig. 9B, lanes 5 and
6). Additionally, the protein-DNA complex migrated at the
same location as the complex observed with purified Osf1 that was not
subjected to an SDS-PAGE (Fig. 9B, lane 1). In contrast, a
DNA binding activity that was recovered from the gel slice containing
the polypeptide migrating at 45 kDa (gel slice A) differed
from the Osf1 binding activity as the observed protein-DNA complex had
a slower mobility in EMSA (Fig. 9B, lane 3). Other fractions
of the SDS gel did not contain detectable binding activities.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 9.
Determination of the apparent molecular
weight of Osf1. A, SDS-PAGE and silver staining of
fractions of the purification scheme. Five µg (lanes 1 and
2) or 2.5 µg (lanes 3 and 4) of
total protein were loaded on the gel, except for lane 5, where 40 µl of the DNA affinity eluate fraction were loaded.
B, polypeptides of the DNA affinity eluate
fraction eluted from gel slices A (lanes 3 and 4) or
B (lanes 5 and 6) as indicated, were
renatured and analyzed for Osf1 binding activity by EMSA using the
wild-type (lanes 1, 3, and 5) or the mutant
OSE1 (lanes 2, 4, and 6) oligonucleotide as a
probe. The binding activity renatured from the indicated portion of the
SDS gel is compared with purified Osf1 that was not subjected to an
SDS-PAGE (lanes 1 and 2). Nonspecific competitor
DNA, poly(dI-dC), was excluded in this experiment.
|
|
 |
DISCUSSION |
Taken together, the results of this study indicate that OSE1 is a
cis-acting element as important as OSE2 in controlling
osteoblast-specific expression of osteocalcin in vivo and
that it may be involved in regulating Cbfa1 expression in
cells of the osteoblast lineage. We also show that the core OSE1
sequence has no overt homologies to binding sites of known
transcription factors. Last, this study provides the first biochemical
characterization of Osf1 and thereby expands the spectrum of regulatory
elements and factors involved in osteoblast-specific gene expression.
To date only one osteoblast-specific transcription factor,
Cbfa1, has been cloned and functionally analyzed using
molecular and genetic means (13-18). All the evidence accumulated
recently demonstrate that Cbfa1 acts as a differentiation
factor in the osteoblast lineage by binding to the OSE2 sites that are
present in the promoters of most genes expressed in osteoblasts (13). Yet, other osteoblast-specific cis-acting elements have been identified in the genes encoding
1(I) collagen, BSP, insulin-like growth factor
1, and osteocalcin (12, 19-25) suggesting the existence of additional
osteoblast-specific transcription factors. OSE1, the element that we
analyzed in this study, is of particular interest as it has been shown
to bind a factor termed Osf1 present only in nuclear extracts of
non-mineralized osteoblasts (12).
We have shown previously that OSE1 could confer osteoblast-specific
activity to a heterologous promoter. However, these studies did not
address the respective importance of OSE1 and OSE2 in the control of
OG2 expression. This is an issue of critical importance that
needed to be addressed before embarking in any further characterization of Osf1. The mutagenesis of OSE1 and OSE2 presented here demonstrates that these cis-acting elements are equally important in controlling OG2 expression. Surprisingly OSE1 appears to be more
important for OG2 expression in transgenic mice than in cell
culture experiments. This may reflect the genetic differences between
osteoblasts in vivo and ROS17/2.8 cells.
OSE1 is also present in the promoter of other osteocalcin genes and of
another gene specific for the osteoblast lineage, Cbfa1. This suggests that Osf1 may be one regulator of Cbfa1
expression in vivo and is consistent with the presence of
Osf1 in nuclear extracts of non-mineralized primary osteoblasts, but
not of fully differentiated osteoblasts. In contrast, OSE1 is not
present in the promoter of the human osteocalcin gene (38). Several
possibilities could explain this finding. We know from previous studies
that the regulation of osteocalcin expression by steroid
hormones such as 1,25-dihydroxyvitamin D3 differs in mouse
and human, indicating a lack of conservation of regulatory mechanisms
between these two species (39, 40). We also know that the serum level
of osteocalcin in humans is significantly lower than in mice (41), suggesting that the human gene is expressed at a lower level. This
could well be explained by the absence of an important regulatory element such as OSE1 in the promoter of human osteocalcin.
Regardless of the reasons explaining this discrepancy the functional
importance of OSE1 for osteocalcin expression in mouse and
the exquisite cell distribution of Osf1 are incentives to study this
factor further.
To determine wether Osf1 belongs to a known family of transcription
factors we defined the 8-bp core OSE1 sequence through an extensive
mutagenesis approach. This sequence, 5'-TTACATCA-3', shows no strong
homology to any binding sites of known transcription factor families,
but a weak similarity to the cAMP-responsive element, the binding site
of CREB proteins (42, 43). However, several important biochemical
characteristics distinguish Osf1 from CREB proteins. First, the CREB
consensus-binding site is palindromic whereas the core OSE1 sequence is
not. Second, Osf1 is heat-sensitive whereas CREB proteins are
heat-stable (34). Third, and more importantly, an A to G mutation in
the core OSE1 sequence that generates a better CRE-like sequence
abolishes binding of Osf1 and results in the binding of an ubiquitously
expressed heat-stable protein, most likely a CREB family member. The
exact molecular nature of Osf1 will be defined when a cDNA becomes available.
The fact that the core OSE1 sequence shows no overt homology to known
transcription factor-binding sites led us to use a classical protein
purification approach to obtain amino acid sequence information. This
approach has been successfully used as an initial step toward the
cloning of several transcription factors (44, 45). Moreover, the
significant progress in protein sequencing by nanospray mass spectrometry enables researchers to sequence unknown proteins at
femtomole quantities (46). This is a critical issue as osteoblasts are
adherent cells, thus precluding us from obtaining large amounts of pure protein.
Initially, Osf1 was identified in ROS17/2.8 osteoblasts (12). However,
nuclear extracts of these cells also contain other factors binding to
the
OSE1 oligonucleotide in EMSA. Although we were able to purify
Osf1 from ROS17/2.8 nuclear extracts, we used C1, another
osteocalcin-expressing cell line (37), as a source of
protein for this purification effort because Osf1 is the only activity
present in C1 nuclear extracts binding to the
OSE1 oligonucleotide.
Moreover, Osf1 is more abundant in C1 than in ROS17/2.8 nuclear
extracts. After a four-step purification, Osf1 migrated as a single
band at 40 kDa in an SDS-PAGE and formed a single complex with the
OSE1 oligonucleotide in EMSA, even in the absence of nonspecific
competitor DNA.
One important question that will need to be addressed in the future is
where Osf1 resides in the genetic cascade controlling osteoblast-specific gene expression and, possibly, osteoblast differentiation. The evidence we have gathered to date can support two
opposite views equally well. The presence of OSE1 in the
osteocalcin promoters and our failure to detect them in the
promoter of other extracellular matrix encoding genes (data not shown)
may indicate that Osf1 acts downstream of Cbfa1 and is required solely
for osteocalcin expression. Alternatively, the fact that an
OSE1 site is present in the Cbfa1 promoter, along with the
presence of Osf1 only in nuclear extracts of non-mineralized
osteoblasts, would rather suggest that Osf1 acts upstream of
Cbfa1. Cbfa1 and Osf1 could also regulate the
expression of each other as it has been shown to be the case for
transcription factors involved in adipogenesis and myogenesis (8, 47).
The distinction between these possibilities will have to await the
molecular cloning of Osf1 and the analysis of its spatial and temporal
expression pattern.
 |
ACKNOWLEDGEMENTS |
We thank Dr. P. Ducy for critically reading
the manuscript and providing the Cbfa1 promoter sequence. We
are also grateful to Dr. A. Poliard and Dr. O. Kellermann (Institute
Pasteur, Paris, France) for kindly providing the C1 cell line and M. Machado and A. Yang for technical support.
 |
FOOTNOTES |
*
This work was supported in part by March of Dimes Grant
1FY96-0175, National Institutes of Health Grants RO1 DE11290 and
AR43655, and Hoechst Marrion Roussel Grant R98006.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by a fellowship of the Deutsche Forschungsgemeinschaft (DFG).
§
To whom correspondence should be addressed: Dept. of Molecular and
Human Genetics, Baylor College of Medicine, Houston, TX 77030. Tel.:
713-798-5489; Fax: 713-798-1465; E-mail: karsenty@bcm.tmc.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
bp, base pair(s);
EMSA, electrophoretic mobility shift assay;
PAGE, polyacrylamide gel
electrophoresis;
CRE, cAMP-responsive element;
CREB, cAMP responsive
element-binding protein;
Osf2, osteoblast-specific factor 2;
Cbfa1, core binding factor
1.
 |
REFERENCES |
| 1.
|
Aubin, J. E.,
and Liu, F.
(1996)
in
Principles of Bone Biology
(Bilezikian, J. P.
, Raisz, L. G.
, and Rodan, G. A., eds)
, pp. 51-67, Academic Press, San Diego, CA
|
| 2.
|
Erlebacher, A.,
Filvaroff, E. H.,
Gitelman, S. E.,
and Derynck, R.
(1995)
Cell
80,
371-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Byers, P. H.,
and Steiner, R. D.
(1992)
Annu. Rev. Med.
43,
269-282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Prockop, D. J.,
and Kivirikko, K. I.
(1984)
N. Engl. J. Med.
311,
376-386[Medline]
[Order article via Infotrieve]
|
| 5.
|
Rowe, D. W.,
and Shapiro, J. R.
(1998)
in
Metabolic Bone Disease
(Avioli, L. V.
, and Krane, S. M., eds)
, pp. 651-678, Academic Press, San Diego, CA
|
| 6.
|
Kleerekoper, M.,
and Avioli, L. V.
(1998)
in
Metabolic Bone Disease
(Avioli, L. V.
, and Krane, S. M., eds)
, pp. 387-389, Academic Press, San Diego, CA
|
| 7.
|
Ishida, Y.,
and Heersche, J. N.
(1998)
J. Bone Miner. Res.
13,
1822-1826[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Wu, Z.,
Rosen, E. D.,
Brun, R.,
Hauser, S.,
Adelmant, G.,
Troy, A. E.,
McKeon, C.,
Darlington, G. J.,
and Spiegelman, B. M.
(1999)
Mol. Cell
3,
151-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Treier, M.,
and Rosenfeld, M. G.
(1996)
Curr. Opin. Cell Biol.
8,
833-843[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Molkentin, J. D.,
Black, B. L.,
Martin, J. F.,
and Olson, E. N.
(1995)
Cell
83,
1125-1136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Orkin, S. H.
(1995)
Curr. Opin. Cell Biol.
7,
870-877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ducy, P.,
and Karsenty, G.
(1995)
Mol. Cell. Biol.
15,
1858-1869[Abstract]
|
| 13.
|
Ducy, P.,
Zhang, R.,
Geoffroy, V.,
Ridall, A. L.,
and Karsenty, G.
(1997)
Cell
89,
747-754[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Komori, T.,
Yagi, H.,
Nomura, S.,
Yamaguchi, A.,
Sasaki, K.,
Deguchi, K.,
Shimizu, Y.,
Bronson, R. T.,
Gao, Y. H.,
Inada, M.,
Sato, M.,
Okamoto, R.,
Kitamura, Y.,
Yoshiki, S.,
and Kishimoto, T.
(1997)
Cell
89,
755-764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Otto, F.,
Thornell, A. P.,
Crompton, T.,
Denzel, A.,
Gilmour, K. C.,
Rosewell, I. R.,
Stamp, G. W. H.,
Beddington, R. S. P.,
Mundlos, S.,
Olsen, B. R.,
Selby, P. B.,
and Owen, M. J.
(1997)
Cell
89,
765-771[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Mundlos, S.,
Otto, F.,
Mundlos, C.,
Mulliken, J. B.,
Aylsworth, A. S.,
Albright, S.,
Lindhout, D.,
Cole, W. G.,
Henn, W.,
Knoll, J. H. M.,
Owen, M. J.,
Mertelsmann, R.,
Zabel, B. U.,
and Olsen, B. R.
(1997)
Cell
89,
773-779[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Lee, B.,
Thirunavukkarasu, K.,
Zhou, L.,
Pastore, L.,
Baldini, A.,
Hecht, J.,
Geoffroy, V.,
Ducy, P.,
and Karsenty, G.
(1997)
Nat. Genet.
16,
307-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Gorski, J. P.,
and Olsen, B. R.
(1998)
Curr. Opin. Cell Biol.
10,
586-593[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Bedalov, A.,
Salvatori, R.,
Dodig, M.,
Kronenberg, M. S.,
Kapural, B.,
Bogdanovic, Z.,
Kream, B. E.,
Woody, C. O.,
Clark, S. H.,
Mack, K.,
Rowe, D. W.,
and Lichtler, A. C.
(1995)
J. Bone Miner. Res.
10,
1443-1451[Medline]
[Order article via Infotrieve]
|
| 20.
|
Rossert, J. A.,
Chen, S. S.,
Eberspaecher, H.,
Smith, C. N.,
and de Crombrugghe, B.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1027-1031[Abstract/Free Full Text]
|
| 21.
|
Chen, J.,
Thomas, H. F.,
Jin, H.,
Jiang, H.,
and Sodek, J.
(1996)
J. Bone Miner. Res.
11,
654-664[Medline]
[Order article via Infotrieve]
|
| 22.
|
Umayahara, Y.,
Ji, C.,
Centrella, M.,
Rotwein, P.,
and McCarthy, T. L.
(1997)
J. Biol. Chem.
272,
31793-31800[Abstract/Free Full Text]
|
| 23.
|
Umayahara, Y.,
Billiard, J.,
Ji, C.,
Centrella, M.,
McCarthy, T. L.,
and Rotwein, P.
(1999)
J. Biol. Chem.
274,
10609-10617[Abstract/Free Full Text]
|
| 24.
|
Montecino, M.,
Pockwinse, S.,
Lian, J.,
Stein, G.,
and Stein, J.
(1994)
Biochemistry
33,
348-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Ryoo, H. M.,
Hoffmann, H. M.,
Beumer, T.,
Frenkel, B.,
Towler, D. A.,
Stein, G. S.,
Stein, J. L.,
van Wijnen, A. J.,
and Lian, J. B.
(1997)
Mol. Endocrinol.
11,
1681-1694[Abstract/Free Full Text]
|
| 26.
|
Frendo, J. L.,
Xiao, G.,
Fuchs, S.,
Franceschi, R. T.,
Karsenty, G.,
and Ducy, P.
(1998)
J. Biol. Chem.
273,
30509-30516[Abstract/Free Full Text]
|
| 27.
|
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K.
(eds)
(1995)
Current Protocol in Molecular Biology
, John Wiley & Sons, Inc., New York
|
| 28.
|
Dignam, J. D.,
Lebowitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 29.
|
Deryckere, F.,
and Gannon, F.
(1994)
BioTechniques
16,
405[Medline]
[Order article via Infotrieve]
|
| 30.
|
Kadonaga, J. T.,
and Tjian, R.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
5889-5893[Abstract/Free Full Text]
|
| 31.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Heukeshoven, J.,
and Dernick, R.
(1988)
Electrophoresis
9,
28-32[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Montminy, M. R.,
Sevarino, K. A.,
Wagner, J. A.,
Mandel, G.,
and Goodman, R. H.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
6682-6686[Abstract/Free Full Text]
|
| 34.
|
Hai, T. W.,
Liu, F.,
Coukos, W. J.,
and Green, M. R.
(1989)
Genes Dev.
3,
2083-2090[Abstract/Free Full Text]
|
| 35.
|
Hai, T. W.,
Liu, F.,
Allegretto, E. A.,
Karin, M.,
and Green, M. R.
(1988)
Genes Dev.
2,
1216-1226[Abstract/Free Full Text]
|
| 36.
|
Desbois, C.,
Hogue, D. A.,
and Karsenty, G.
(1994)
J. Biol. Chem.
269,
1183-1190[Abstract/Free Full Text]
|
| 37.
|
Poliard, A.,
Lamblin, D.,
Marie, P. J.,
Buc-Caron, M. H.,
and Kellermann, O.
(1993)
J. Cell Sci.
106,
503-511[Abstract]
|
| 38.
|
Morrison, N. A.,
Shine, J.,
Fragonas, J. C.,
Verkest, V.,
McMenemy, M. L.,
and Eisman, J. A.
(1989)
Science
246,
1158-1161[Abstract/Free Full Text]
|
| 39.
|
Zhang, R.,
Ducy, P.,
and Karsenty, G.
(1997)
J. Biol. Chem.
272,
110-116[Abstract/Free Full Text]
|
| 40.
|
Clemens, T. L.,
Tang, H.,
Maeda, S.,
Kesterson, R. A.,
Demayo, F.,
Pike, J. W.,
and Gundberg, C. M.
(1997)
J. Bone Miner. Res.
12,
1570-1576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Hauschka, P. V.,
Lian, J. B.,
Cole, D. E.,
and Gundberg, C. M.
(1989)
Physiol. Rev.
69,
990-1047[Free Full Text]
|
| 42.
|
Montminy, M. R.,
and Bilezikijan, L. M.
(1987)
Nature
328,
175-178[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Hoeffler, J. P.,
Meyer, T. E.,
Yun, Y.,
Jameson, J. L.,
and Habener, J. F.
(1988)
Science
242,
1430-1433[Abstract/Free Full Text]
|
| 44.
|
Landschulz, W. H.,
Johnson, P. F.,
Adashi, E. Y.,
Graves, B. J.,
and McKnight, S. L.
(1988)
Genes Dev.
2,
786-800[Abstract/Free Full Text]
|
| 45.
|
Kadonaga, J. T.,
Carner, K. R.,
Masiarz, F. R.,
and Tjian, R.
(1987)
Cell
51,
1079-1090[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Arnott, D.,
Shabanowitz, J.,
and Hunt, D. F.
(1993)
Clin. Chem.
39,
2005-2010[Abstract]
|
| 47.
|
Edmondson, D. G.,
Cheng, T. C.,
Cserjesi, P.,
Chakraborty, T.,
and Olson, E. N.
(1992)
Mol. Cell. Biol.
12,
3665-3677[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: